SCHEMBL17309381

SCHEMBL17309381

CCOc1ccc(/C=C2\S/C(=N\c3ccccc3)N(C)C2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 3/20 0.66
▸ LMNA P02545 2/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ ITGB3 P05106 2/20 0.60
▸ ITGAV P06756 2/20 0.60
▸ MEN1 O00255 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MGAM O43451 2/20 0.58
▸ CA12 O43570 2/20 0.58
▸ CA1 P00915 2/20 0.58
▸ CA2 P00918 2/20 0.58
▸ CA9 Q16790 2/20 0.58
▸ DUSP26 Q9BV47 3/20 0.58
▸ FAAH O00519 1/20 0.56
▸ HPGD P15428 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12177712 0.83 AURKA (0.75) AURKALMNATDP1MGAMCA12
SCHEMBL12177682 0.81 CA9 (0.70) AURKALMNATDP1MEN1ALDH1A1
SCHEMBL12177166 0.80 AURKA (0.70) AURKALMNATDP1MEN1ALDH1A1
SCHEMBL5281534 0.79 MAPK1 (0.72) LMNATDP1MEN1ALDH1A1KMT2A
SCHEMBL5281527 0.79 MAPK1 (0.72) LMNATDP1MEN1ALDH1A1KMT2A
SCHEMBL5281537 0.79 MAPK1 (0.72) LMNATDP1MEN1ALDH1A1KMT2A
SCHEMBL12177573 0.78 AURKA (0.60) AURKALMNATDP1MGAMCA12
SCHEMBL4057081 0.77 PTPN1 (0.76) AURKADUSP26
SCHEMBL4057079 0.77 PTPN1 (0.76) AURKADUSP26
SCHEMBL12177685 0.77 AURKA (0.65) AURKALMNATDP1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148541-B1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIV BERN (CH) 2020-09-02 — — EP disclosed
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-10-19 — — US disclosed
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIVERSITAT BERN (CH) 2017-10-19 — — US disclosed
EP-2952188-A1 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation Universität Bern (CH) 2015-12-09 — — EP disclosed
WO-2015181336-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION Universität Bern (CH) 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170296515-A1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION SLC18A2, AANAT, CNR2 AURKA 1029/4885LMNA 3797/4885TDP1 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback